Performance Insights and Support for a Smooth Transition We are excited to introduce our second-generation iLite® cells, designed to optimize your bioassay workflows and enhance data reliability. This blog post provides an in-depth look at the performance studies conducted on these new cell lines ... Read more
Introducing iLite® IFN FAST second-generation assay-ready cells Effective bioassays are crucial in pharmaceutical development for assessing potency and detecting neutralizing antibodies in immunogenicity studies. Our iLite IFN FAST second-generation cells offer shorter incubation times, Renilla ... Read more
Therapeutic antibodies have revolutionized biopharmaceutical drug development, offering targeted treatments for a range of diseases, from autoimmune disorders to oncology. However, immunogenicity remains a critical hurdle, as the formation of anti-drug antibodies (ADAs) can impact drug efficacy, ... Read more
Therapeutic antibodies have transformed modern biopharmaceuticals, providing targeted and highly specific treatments for a range of diseases, including oncology, autoimmune disorders, and infectious diseases. However, immunogenicity concerns, particularly the development of anti-drug antibodies ... Read more
